Quince Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Quince Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2023.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$27.7M, a 468% decline year-over-year.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$53.1M, a 73.6% decline year-over-year.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.4M, a 39.2% increase from 2022.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$51.7M, a 42.6% increase from 2021.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.9M, a 17% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$31.4M +$20.3M +39.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-04-01
2022 -$51.7M +$38.3M +42.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 -$89.9M -$13.1M -17% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$76.8M -$39.9M -108% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-01
2019 -$37M -$24.5M -196% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$12.5M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.